| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets
U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension
COMMACK, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10mg/mL, is commercially available through full-line wholesalers nationwide. This milestone establishes Arbli™ (www.arbli.com) as the first and only FDA-approved ready-to-use liquid losartan formulation accessible through established pharmaceutical distribution channels across the United States. Losartan, an angiotensin II receptor blocker (ARB), is widely prescribed for the treatment of high blood pressure.
Posted In: SCNX
